The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study
- 29 November 2018
- journal article
- research article
- Published by Taylor & Francis in Biomarkers
- Vol. 24 (3) , 255-261
Abstract
Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into 2 groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (Continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; Switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) didn’t change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the Switch group without renal function deterioration (Switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.Keywords
This publication has 36 references indexed in Scilit:
- A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effectsHypertension Research, 2010
- Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO studyEuropean Heart Journal, 2009
- Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause DeathArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Expression of pentraxin 3 (PTX3) in human atherosclerotic lesionsThe Journal of Pathology, 2007
- Normotensive Ischemic Acute Renal FailureNew England Journal of Medicine, 2007
- Low-Grade Inflammation Is a Risk Factor for Clinical Stroke Events in Addition to Silent Cerebral Infarcts in Japanese Older HypertensivesStroke, 2007
- Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and MicroalbuminuriaDiabetes, 2006
- Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular EventsCirculation, 2003
- Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trialsBlood Pressure, 1992